GXYLT1

Summary

GXYLT1 (glucoside xylosyltransferase 1, HGNC:27482) is a protein-coding gene on chromosome 12q12, encoding Glucoside xylosyltransferase 1 (Q4G148). Glycosyltransferase which elongates the O-linked glucose attached to EGF-like repeats in the extracellular domain of Notch proteins by catalyzing the addition of xylose.

GXYLT1 is a xylosyltransferase (EC 2.4.2.-) that adds the first xylose to O-glucose-modified residues in the epidermal growth factor (EGF; MIM 131530) repeats of proteins such as NOTCH1 (MIM 190198) (Sethi et al., 2010 [PubMed 19940119]).

Source: NCBI Gene 283464 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 84 total
• MANE Select transcript: NM_173601

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27482
Approved symbol	GXYLT1
Name	glucoside xylosyltransferase 1
Location	12q12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ43151
Ensembl gene	ENSG00000151233
Ensembl biotype	protein_coding
OMIM	613321
Entrez	283464

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000280876, ENST00000398675, ENST00000905120, ENST00000905121

RefSeq mRNA: 2 — MANE Select: NM_173601 NM_001099650, NM_173601

CCDS: CCDS41771, CCDS41772

Canonical transcript exons

ENST00000398675 — 8 exons

Exon	Start	End
ENSE00000998426	42105818	42106069
ENSE00001098513	42081845	42087947
ENSE00001098514	42097910	42098033
ENSE00001098515	42097442	42097614
ENSE00001219672	42109566	42109691
ENSE00001219680	42119000	42119171
ENSE00001219699	42144426	42144874
ENSE00001534300	42129759	42129851

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 87.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.3444 / max 57.2026, expressed in 1672 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130477	3.1328	1384
130475	2.2116	1305

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	87.41	gold quality
parietal pleura	UBERON:0002400	86.91	gold quality
adrenal tissue	UBERON:0018303	86.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.28	gold quality
visceral pleura	UBERON:0002401	86.28	gold quality
placenta	UBERON:0001987	86.22	gold quality
germinal epithelium of ovary	UBERON:0001304	84.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.44	gold quality
epithelial cell of pancreas	CL:0000083	83.97	silver quality
thymus	UBERON:0002370	83.72	gold quality
palpebral conjunctiva	UBERON:0001812	83.19	gold quality
tibia	UBERON:0000979	82.92	gold quality
calcaneal tendon	UBERON:0003701	82.75	gold quality
jejunal mucosa	UBERON:0000399	82.65	gold quality
islet of Langerhans	UBERON:0000006	81.85	gold quality
seminal vesicle	UBERON:0000998	81.36	gold quality
epithelium of nasopharynx	UBERON:0001951	81.03	gold quality
lower lobe of lung	UBERON:0008949	80.64	gold quality
monocyte	CL:0000576	80.60	gold quality
leukocyte	CL:0000738	80.21	gold quality
endometrium	UBERON:0001295	80.09	gold quality
ileal mucosa	UBERON:0000331	79.69	gold quality
stromal cell of endometrium	CL:0002255	79.32	gold quality
pericardium	UBERON:0002407	78.71	gold quality
ganglionic eminence	UBERON:0004023	78.37	gold quality
mucosa of sigmoid colon	UBERON:0004993	78.37	gold quality
embryo	UBERON:0000922	78.36	gold quality
epithelium of mammary gland	UBERON:0003244	78.36	gold quality
mammary duct	UBERON:0001765	78.32	gold quality
cartilage tissue	UBERON:0002418	78.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.12

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

357 targeting GXYLT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955

Literature-anchored findings (GeneRIF, showing 3)

• We have identified two enzymes of the human glycosyltransferase 8 family, now named GXYLT1 and GXYLT2 (glucoside xylosyltransferase), as UDP-d-xylose:beta-d-glucoside alpha1,3-d-xylosyltransferases adding the first xylose. (PMID:19940119)
• A stop-gain mutation in GXYLT1 promotes metastasis of colorectal cancer via the MAPK pathway. (PMID:35459861)
• Exome Sequencing Implicates DGKZ , ESRRA , and GXYLT1 for Modulating Granuloma Formation in Crohn Disease. (PMID:37347142)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	gxylt1b	ENSDARG00000022550
danio_rerio		ENSDARG00000076111
mus_musculus	Gxylt1	ENSMUSG00000036197
rattus_norvegicus	Gxylt1	ENSRNOG00000005234
drosophila_melanogaster	CG11149	FBGN0031732
drosophila_melanogaster	CG9171	FBGN0031738
drosophila_melanogaster	CG15483	FBGN0032457
drosophila_melanogaster	shams	FBGN0039273
caenorhabditis_elegans	bgnt-1.8	WBGENE00008290
caenorhabditis_elegans		WBGENE00009032
caenorhabditis_elegans	bgnt-1.6	WBGENE00010167
caenorhabditis_elegans		WBGENE00010694
caenorhabditis_elegans		WBGENE00010716
caenorhabditis_elegans	bgnt-1.7	WBGENE00011779
caenorhabditis_elegans		WBGENE00015982
caenorhabditis_elegans		WBGENE00017723

Paralogs (5): LARGE1 (ENSG00000133424), LARGE2 (ENSG00000165905), GXYLT2 (ENSG00000172986), XXYLT1 (ENSG00000173950), B4GAT1 (ENSG00000174684)

Protein

Protein identifiers

Glucoside xylosyltransferase 1 — Q4G148 (reviewed: Q4G148)

Alternative names: Glycosyltransferase 8 domain-containing protein 3

All UniProt accessions (1): Q4G148

UniProt curated annotations — full annotation on UniProt →

Function. Glycosyltransferase which elongates the O-linked glucose attached to EGF-like repeats in the extracellular domain of Notch proteins by catalyzing the addition of xylose.

Subcellular location. Membrane.

Similarity. Belongs to the glycosyltransferase 8 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q4G148-1	1	yes
Q4G148-2	2

RefSeq proteins (2): NP_001093120, NP_775872* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002495	Glyco_trans_8	Family
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily
IPR051993	Glycosyltransferase_8	Family

Pfam: PF01501

Catalyzed reactions (Rhea), 1 shown:

• 3-O-(beta-D-glucosyl)-L-seryl-[EGF-like domain protein] + UDP-alpha-D-xylose = 3-O-[alpha-D-xylosyl-(1->3)-beta-D-glucosyl]-L-seryl-[EGF-like domain protein] + UDP + H(+) (RHEA:56064)

UniProt features (9 total): glycosylation site 3, topological domain 2, chain 1, transmembrane region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q4G148-F1	85.06	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 173, 237, 278

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 219 (showing top): chr12q12, IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, MILI_PSEUDOPODIA_CHEMOTAXIS_UP, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION_VIA_N_ACETYL_GALACTOSAMINE, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, GOMF_GLYCOSYLTRANSFERASE_ACTIVITY, GOMF_UDP_GLYCOSYLTRANSFERASE_ACTIVITY, GOMF_PENTOSYLTRANSFERASE_ACTIVITY, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP, CHICAS_RB1_TARGETS_SENESCENT, JOHNSTONE_PARVB_TARGETS_2_DN

GO Biological Process (2): protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266), protein O-linked glycosylation via glucose (GO:0180059)

GO Molecular Function (4): UDP-xylosyltransferase activity (GO:0035252), UDP-D-xylose:beta-D-glucoside alpha-1,3-D-xylosyltransferase activity (GO:0140563), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein O-linked glycosylation	2
UDP-glycosyltransferase activity	1
xylosyltransferase activity	1
UDP-xylosyltransferase activity	1
catalytic activity	1
transferase activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

806 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GXYLT1	UGGT1	Q9NYU2	895
GXYLT1	F7	P08709	778
GXYLT1	POGLUT1	Q8NBL1	725
GXYLT1	POGLUT2	Q6UW63	628
GXYLT1	NOTCH1	P46531	596
GXYLT1	ZCRB1	Q8TBF4	583
GXYLT1	POGLUT3	Q7Z4H8	575
GXYLT1	POFUT1	Q9H488	566
GXYLT1	ZNF782	Q6ZMW2	563
GXYLT1	EGF	P01133	523
GXYLT1	XXYLT1	Q8NBI6	511
GXYLT1	EOGT	Q5NDL2	502
GXYLT1	TMEM117	Q9H0C3	454
GXYLT1	RBM46	Q8TBY0	437
GXYLT1	XYLT1	Q86Y38	436

IntAct

34 interactions, top by confidence:

A	B	Type	Score
CHCHD4	SSNA1	psi-mi:“MI:0914”(association)	0.640
GXYLT1	CANX	psi-mi:“MI:0914”(association)	0.640
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
TOR1AIP1	TXN	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
ALK	PIK3R2	psi-mi:“MI:0914”(association)	0.420
IGF1R	HAX1	psi-mi:“MI:0914”(association)	0.350
INSR	HAX1	psi-mi:“MI:0914”(association)	0.350
TYRO3	HAX1	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
GXYLT1	P4HB	psi-mi:“MI:0914”(association)	0.350
PCDHB3	ESYT2	psi-mi:“MI:0914”(association)	0.350
TMEM106A	TMEM131L	psi-mi:“MI:0914”(association)	0.350
PDGFRA	QSOX1	psi-mi:“MI:0914”(association)	0.350
EPHA7	PLOD2	psi-mi:“MI:0914”(association)	0.350
ALPP	MAN2B1	psi-mi:“MI:0914”(association)	0.350
EFNA2	MGST3	psi-mi:“MI:0914”(association)	0.350
GXYLT1	CLGN	psi-mi:“MI:0914”(association)	0.350
HTR1B	SCAMP2	psi-mi:“MI:0914”(association)	0.350
AIFM1	HSPA12A	psi-mi:“MI:0914”(association)	0.350
CHCHD4	PDHX	psi-mi:“MI:0914”(association)	0.350
LCN6	HIGD1C	psi-mi:“MI:0914”(association)	0.350
SLC30A10	GOLIM4	psi-mi:“MI:0914”(association)	0.350
SLC39A11	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A14	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A7	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC39A9	TRAFD1	psi-mi:“MI:0914”(association)	0.350
FBXO11	GXYLT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (120): P4HB (Affinity Capture-MS), CANX (Affinity Capture-MS), P2RX2 (Affinity Capture-MS), OMA1 (Affinity Capture-MS), FKBP14 (Affinity Capture-MS), ASPHD2 (Affinity Capture-MS), NPTX1 (Affinity Capture-MS), VIM (Affinity Capture-MS), GXYLT1 (Affinity Capture-MS), GXYLT1 (Synthetic Lethality), GXYLT1 (Proximity Label-MS), GXYLT1 (Affinity Capture-MS), GXYLT1 (Reconstituted Complex), GXYLT1 (Proximity Label-MS), GXYLT1 (Proximity Label-MS)

ESM2 similar proteins: A0PJZ3, A2XFP3, A2XFT5, A2XFT6, B8AIZ4, C7J0P3, O04536, O48684, O88829, P08037, P15291, P15535, Q02527, Q09327, Q0V7R1, Q0WV13, Q10470, Q10MK2, Q10MQ0, Q16842, Q3UHH8, Q4G148, Q5CAZ6, Q5K027, Q5MJS3, Q5SP46, Q5ZKI6, Q68G12, Q6DE37, Q6GX83, Q6H765, Q6KB58, Q701R2, Q70D51, Q810K9, Q8CID3, Q8GWT1, Q8IXL6, Q8RXE1, Q92184

Diamond homologs: A0PJZ3, Q3UHH8, Q4G148, Q5SP46, Q5ZKI6, Q6DE37, Q6GX83, Q810K9, Q3U4G3

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
GXYLT1	up-regulates	NOTCH1	glycosylation
GXYLT1	up-regulates	NOTCH2	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 48 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
zinc ion transmembrane transport	5	79.8×	2e-06
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	6	10.7×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

84 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	19
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1746 predictions. Top by Δscore:

Variant	Effect	Δscore
12:42097436:TCTTA:T	donor_loss	1.0000
12:42097437:CTTAC:C	donor_loss	1.0000
12:42097438:TTA:T	donor_loss	1.0000
12:42097439:TACAT:T	donor_loss	1.0000
12:42097440:A:AC	donor_gain	1.0000
12:42097440:ACA:A	donor_loss	1.0000
12:42097441:C:CA	donor_gain	1.0000
12:42097441:CA:C	donor_gain	1.0000
12:42097441:CAT:C	donor_gain	1.0000
12:42097441:CATT:C	donor_gain	1.0000
12:42097441:CATTT:C	donor_gain	1.0000
12:42097587:C:T	acceptor_gain	1.0000
12:42097587:CAT:C	acceptor_gain	1.0000
12:42097589:T:TC	acceptor_gain	1.0000
12:42097593:C:CT	acceptor_gain	1.0000
12:42097595:C:CT	acceptor_gain	1.0000
12:42097596:G:T	acceptor_gain	1.0000
12:42097611:CTTT:C	acceptor_gain	1.0000
12:42097613:TT:T	acceptor_gain	1.0000
12:42097615:C:CC	acceptor_gain	1.0000
12:42098029:TCATT:T	acceptor_gain	1.0000
12:42098030:CATTC:C	acceptor_gain	1.0000
12:42098034:C:CC	acceptor_gain	1.0000
12:42105814:TTACC:T	donor_loss	1.0000
12:42105815:TACCT:T	donor_loss	1.0000
12:42105816:AC:A	donor_gain	1.0000
12:42105817:CC:C	donor_gain	1.0000
12:42105829:T:TA	donor_gain	1.0000
12:42105962:T:C	acceptor_gain	1.0000
12:42106066:TTAA:T	acceptor_gain	1.0000

AlphaMissense

2893 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:42105869:G:C	N271K	1.000
12:42105869:G:T	N271K	1.000
12:42105905:A:C	F259L	1.000
12:42105905:A:T	F259L	1.000
12:42105907:A:G	F259L	1.000
12:42106026:T:A	D219V	1.000
12:42106026:T:G	D219A	1.000
12:42106032:T:A	D217V	1.000
12:42109599:A:C	F193L	1.000
12:42109599:A:T	F193L	1.000
12:42109600:A:C	F193C	1.000
12:42109601:A:G	F193L	1.000
12:42097503:C:A	R367I	0.999
12:42097503:C:G	R367T	0.999
12:42097509:C:T	G365E	0.999
12:42097513:G:C	H364D	0.999
12:42097565:A:C	C346W	0.999
12:42097566:C:G	C346S	0.999
12:42097567:A:T	C346S	0.999
12:42097583:A:C	N340K	0.999
12:42097583:A:T	N340K	0.999
12:42097932:A:C	N322K	0.999
12:42097932:A:T	N322K	0.999
12:42097939:A:G	L320P	0.999
12:42097942:T:A	D319V	0.999
12:42097942:T:G	D319A	0.999
12:42097943:C:G	D319H	0.999
12:42097944:T:A	Q318H	0.999
12:42097944:T:G	Q318H	0.999
12:42097948:T:A	D317V	0.999

dbSNP variants (sampled 300 via entrez): RS1000057471 (12:42125835 C>A,T), RS1000079230 (12:42119697 A>C), RS1000112666 (12:42098724 T>A,G), RS1000114745 (12:42131787 A>G), RS1000181488 (12:42140049 C>T), RS1000183005 (12:42090134 G>A), RS1000188262 (12:42146124 CAGAG>C,CAG), RS1000252466 (12:42132081 A>C,G), RS1000259356 (12:42111844 T>A,C), RS1000320371 (12:42120303 C>T), RS1000327793 (12:42096380 G>C), RS1000331806 (12:42111934 C>A), RS1000442396 (12:42096602 T>C), RS1000459380 (12:42135771 G>A,C), RS1000560306 (12:42094738 A>C)

Disease associations

OMIM: gene MIM:613321 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary amenorrhea (MONDO:1060208)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST006585_2318	Blood protein levels	3.000000e-42
GCST007821_3	Facial attractiveness (female raters)	6.000000e-07
GCST008062_118	Blood urea nitrogen levels	2.000000e-08
GCST009325_101	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	2.000000e-10
GCST009325_76	Parkinson’s disease or first degree relation to individual with Parkinson’s disease	7.000000e-12
GCST010002_215	Refractive error	3.000000e-11
GCST010774_11	Essential hypertension (time to event)	5.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009892	facial attractiveness measurement
EFO:0004918	age at diagnosis

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
perfluorooctane sulfonic acid	decreases expression	2
Air Pollutants	decreases expression, increases abundance	2
Formaldehyde	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
decabromobiphenyl ether	increases expression	1
2-butenal	decreases expression	1
tetrabromobisphenol A	increases expression	1
perfluorooctanoic acid	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
picoxystrobin	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Fulvestrant	increases methylation	1
Vorinostat	decreases expression	1
Leflunomide	decreases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	increases expression	1
Cadmium	increases expression	1
Coal	increases abundance, decreases expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07164248	Not specified	COMPLETED	Evaluation of Bone Mineral Density Indications and Outcomes in Female Adolescents: Implications for Early Detection of Osteopenia/Osteoporosis and Gynecologic Practice